<DOC>
	<DOCNO>NCT00343863</DOCNO>
	<brief_summary>RATIONALE : Antiemetic drug , dexamethasone , ondansetron hydrochloride , palonosetron hydrochloride , may help lessen prevent nausea vomit cause chemotherapy . PURPOSE : This clinical trial study well give dexamethasone together ondansetron hydrochloride palonosetron hydrochloride work prevent nausea vomit patient receive doxorubicin hydrochloride cyclophosphamide early stage breast cancer</brief_summary>
	<brief_title>Dexamethasone Ondansetron Hydrochloride Palonosetron Hydrochloride Preventing Nausea Vomiting Patients Receiving Doxorubicin Hydrochloride Cyclophosphamide For Early Stage Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine proportion patient achieve complete response ( CR ) , define emesis rescue medication 0-24 hour time period follow weekly intravenous doxorubicin . SECONDARY OBJECTIVES : I . To determine proportion patient achieve complete response ( CR ) , define emesis rescue medication 24-120 hour time period follow weekly intravenous doxorubicin . II . To determine proportion patient achieve complete response ( CR ) , define emesis rescue medication 0-120 hour time period follow weekly intravenous doxorubicin . III . To determine number emetic episode daily cumulatively 24-120 , 0-120 hour time period . IV . To determine time first emetic episode . V. To determine time first administration rescue medication . VI . To determine time treatment failure ( time first emetic episode administration rescue medication , whichever occur first ) . VII . To determine number dos rescue medication use . VIII . To determine side effect antiemetic medication use . IX . To determine theseverity nausea . X . To evaluate quality life . OUTLINE : Patients assign 1 2 treatment group . All patient receive doxorubicin hydrochloride IV day 1 oral cyclophosphamide day 1-7 . GROUP I : Patients receive dexamethasone IV orally ondansetron IV day 1 ( prior dose doxorubicin hydrochloride ) . GROUP II : Patients receive dexamethasone IV orally palonosetron IV day 1 ( prior dose doxorubicin hydrochloride ) . Treatment repeat every 7 day 12-15 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Patients must histologically confirm diagnosis primary breast carcinoma Patient must naive chemotherapy time enrollment Patients must prescribe weekly intravenous adriamycin ( doxorubicin ) daily oral cyclophosphamide treatment early breast cancer The patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline Patients must Karnofsky index great equal 50 % Known mild moderate hepatic , renal cardiovascular impairment may enrol discretion investigator Receipt investigational drug within 30 day study entry Received drug potential antiemetic effect within 24 hour prior start studydesignated chemotherapeutic agent ( exception administration palonosetron/dexamethasone infusion solution ) , include follow : 5HT3 receptor antagonist ; dopamine receptor antagonist ( metoclopramide ) ; phenothiazine antiemetic ( prochlorperazine , thiethylperazine perphenazine ) ; diphenhydramine , scopolamine , chlorpheniramine maleate , trimethobenzamide ( diphenhydramine allow give prophylactic treatment hypersensitivity reaction associate administration Taxanes ) ; benzodiazepine ; haloperidol , droperidol , tetrahydrocannabinol , nabilone ; systemic corticosteroid ( hydrocortisone , methylprednisolone , prednisone ) ( topical inhale preparation allow ) Any vomiting , retch NCI Common Toxicity Criteria version 3.0 grade 24 nausea 24 hour precede chemotherapy Ongoing vomit organic etiology Need receive systemic corticosteroid , except : ) define part chemotherapy regimen preventative measure chemotherapy toxicity ; b ) topical inhaled preparation ; and/or c ) use rescue medication study Known contraindication 5HT3 receptor antagonist ( include palonosetron ) dexamethasone Need receive radiotherapy study Inability understand cooperate study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>